Search results
The FDA approved Zepbound (tirzepatide) injection for chronic weight management in adults with obesity or overweight with at least one weight-related condition, for use in addition to a...
8 lis 2023 · Zepbound™ (ZEHP-bownd) is an injectable prescription medicine that may help adults with obesity, or with excess weight (overweight) who also have weight-related medical problems, lose weight and keep it off. It should be used with a reduced-calorie diet and increased physical activity.
8 lis 2023 · The Food and Drug Administration on Wednesday approved an obesity drug from the company Eli Lilly that will be a direct competitor to the wildly popular Wegovy. The drug is called tirzepatide...
8 lis 2023 · The FDA has approved Zepbound, an injectable weight loss drug from Eli Lilly that helped people lose up to 52 lbs in 16 months during clinical trials.
6 paź 2022 · Based on discussions with the FDA, Lilly plans to initiate a rolling submission of a new drug application (NDA) for tirzepatide in adults with obesity or overweight this year, which when complete, will be based primarily on results from two Phase 3 clinical trials: SURMOUNT-1, which is complete, and SURMOUNT-2, which is expected to complete by ...
8 lis 2023 · Drugmaker Eli Lilly & Co. received Food and Drug Administration approval for an obesity drug called Zepbound that will be a rival to Novo Nordisk's Wegovy.
News Release. FDA approves Lilly's Mounjaro™ (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes. May 13, 2022. PDF Version. Mounjaro delivered superior A1C reductions versus all comparators in phase 3 SURPASS clinical trials.
